APO Research
Talk to an analyst

APO RESEARCH · REPORT

Solid Dosage Form Drug

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Solid Dosage Form Drug Market Outlook and Growth Opportunities 2026

21 December 2025201 pages

Choose your research edition.

Industry ResearchSolid Dosage Form Drug Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Solid Dosage Form Drug Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Solid Dosage Form Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Solid Dosage Form Drug Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Solid Dosage Form Drug Market Analysis and Forecast 2026-2032204 pages · $4,950 USD

Market perspective

The global Solid Dosage Form Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Solid Dosage Form Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Solid Dosage Form Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Solid Dosage Form Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Solid Dosage Form Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Solid Dosage Form Drug market include Takeda, Teva, Sanofi, Johnson & Johnson, Novartis, Roche, Eli Lilly & Co., Pfizer and GlaxoSmithKline, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Solid Dosage Form Drug market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Solid Dosage Form Drug and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Solid Dosage Form Drug revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Solid Dosage Form Drug market.

Solid Dosage Form Drug Segment by Company

Takeda

Teva

Sanofi

Johnson & Johnson

Novartis

Roche

Eli Lilly & Co.

Pfizer

GlaxoSmithKline

Biogen

Bayer

Bristol Myers Squibb

Amgen

AbbVie

AstraZeneca

Merck & Co.

Gilead Sciences

Boehringer Ingelheim

Astellas

Solid Dosage Form Drug Segment by Type

Tablet

Capsules

Other

Solid Dosage Form Drug Segment by Application

Hospital

Retail Pharmacy

Other

Solid Dosage Form Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Solid Dosage Form Drug status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Solid Dosage Form Drug key companies, revenue, market share, and recent developments.

3. To split the Solid Dosage Form Drug breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Solid Dosage Form Drug market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Solid Dosage Form Drug significant trends, drivers, influence factors in global and regions.

6. To analyze Solid Dosage Form Drug competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Solid Dosage Form Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Solid Dosage Form Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Solid Dosage Form Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Solid Dosage Form Drug industry.

Chapter 3: Detailed analysis of Solid Dosage Form Drug company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Solid Dosage Form Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Solid Dosage Form Drug in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Solid Dosage Form Drug Industry Trends Table 2. Solid Dosage Form Drug Industry Drivers Table 3. Solid Dosage Form Drug Industry Opportunities and Challenges Table 4. Solid Dosage Form Drug Industry Restraints Table 5. Global Solid Dosage Form Drug Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Solid Dosage Form Drug Revenue Share by Company (2021-2026) Table 7. Global Solid Dosage Form Drug Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Solid Dosage Form Drug Key Company Manufacturing Base & Headquarters Table 9. Global Solid Dosage Form Drug Company, Product Type & Application Table 10. Global Solid Dosage Form Drug Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Solid Dosage Form Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Tablet Table 15. Significant Companies of Capsules Table 16. Significant Companies of Other Table 17. Global Solid Dosage Form Drug Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Solid Dosage Form Drug Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Solid Dosage Form Drug Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Solid Dosage Form Drug Sales Value Share by Type (2021-2026) Table 21. Global Solid Dosage Form Drug Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Hospital Table 23. Significant Companies of Retail Pharmacy Table 24. Significant Companies of Other Table 25. Global Solid Dosage Form Drug Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Solid Dosage Form Drug Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Solid Dosage Form Drug Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Solid Dosage Form Drug Sales Value Share by Application (2021-2026) Table 29. Global Solid Dosage Form Drug Sales Value Share by Application (2027-2032) Table 30. Global Solid Dosage Form Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Solid Dosage Form Drug Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Solid Dosage Form Drug Sales Value Share by Region (2021-2026) Table 33. Global Solid Dosage Form Drug Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Solid Dosage Form Drug Sales Value Share by Region (2027-2032) Table 35. Global Solid Dosage Form Drug Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Solid Dosage Form Drug Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Solid Dosage Form Drug Sales Value Market Share by Country (2021-2026) Table 38. Global Solid Dosage Form Drug Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Solid Dosage Form Drug Sales Value Market Share by Country (2027-2032) Table 40. Takeda Company Information Table 41. Takeda Business Overview Table 42. Takeda Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Takeda Solid Dosage Form Drug Product Portfolio Table 44. Takeda Recent Development Table 45. Teva Company Information Table 46. Teva Business Overview Table 47. Teva Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Teva Solid Dosage Form Drug Product Portfolio Table 49. Teva Recent Development Table 50. Sanofi Company Information Table 51. Sanofi Business Overview Table 52. Sanofi Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Sanofi Solid Dosage Form Drug Product Portfolio Table 54. Sanofi Recent Development Table 55. Johnson & Johnson Company Information Table 56. Johnson & Johnson Business Overview Table 57. Johnson & Johnson Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Johnson & Johnson Solid Dosage Form Drug Product Portfolio Table 59. Johnson & Johnson Recent Development Table 60. Novartis Company Information Table 61. Novartis Business Overview Table 62. Novartis Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Novartis Solid Dosage Form Drug Product Portfolio Table 64. Novartis Recent Development Table 65. Roche Company Information Table 66. Roche Business Overview Table 67. Roche Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Roche Solid Dosage Form Drug Product Portfolio Table 69. Roche Recent Development Table 70. Eli Lilly & Co. Company Information Table 71. Eli Lilly & Co. Business Overview Table 72. Eli Lilly & Co. Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Eli Lilly & Co. Solid Dosage Form Drug Product Portfolio Table 74. Eli Lilly & Co. Recent Development Table 75. Pfizer Company Information Table 76. Pfizer Business Overview Table 77. Pfizer Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Pfizer Solid Dosage Form Drug Product Portfolio Table 79. Pfizer Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. GlaxoSmithKline Solid Dosage Form Drug Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Biogen Company Information Table 86. Biogen Business Overview Table 87. Biogen Solid Dosage Form Drug Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Biogen Solid Dosage Form Drug Product Portfolio Table 89. Biogen Recent Development Table 90. Bayer Company Information Table 91. Bayer Business Overview Table 92. Bayer Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 93. Bayer Solid Dosage Form Drug Product Portfolio Table 94. Bayer Recent Development Table 95. Bristol Myers Squibb Company Information Table 96. Bristol Myers Squibb Business Overview Table 97. Bristol Myers Squibb Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 98. Bristol Myers Squibb Solid Dosage Form Drug Product Portfolio Table 99. Bristol Myers Squibb Recent Development Table 100. Amgen Company Information Table 101. Amgen Business Overview Table 102. Amgen Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 103. Amgen Solid Dosage Form Drug Product Portfolio Table 104. Amgen Recent Development Table 105. AbbVie Company Information Table 106. AbbVie Business Overview Table 107. AbbVie Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 108. AbbVie Solid Dosage Form Drug Product Portfolio Table 109. AbbVie Recent Development Table 110. AstraZeneca Company Information Table 111. AstraZeneca Business Overview Table 112. AstraZeneca Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 113. AstraZeneca Solid Dosage Form Drug Product Portfolio Table 114. AstraZeneca Recent Development Table 115. Merck & Co. Company Information Table 116. Merck & Co. Business Overview Table 117. Merck & Co. Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 118. Merck & Co. Solid Dosage Form Drug Product Portfolio Table 119. Merck & Co. Recent Development Table 120. Gilead Sciences Company Information Table 121. Gilead Sciences Business Overview Table 122. Gilead Sciences Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 123. Gilead Sciences Solid Dosage Form Drug Product Portfolio Table 124. Gilead Sciences Recent Development Table 125. Boehringer Ingelheim Company Information Table 126. Boehringer Ingelheim Business Overview Table 127. Boehringer Ingelheim Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 128. Boehringer Ingelheim Solid Dosage Form Drug Product Portfolio Table 129. Boehringer Ingelheim Recent Development Table 130. Astellas Company Information Table 131. Astellas Business Overview Table 132. Astellas Solid Dosage Form Drug Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 133. Astellas Solid Dosage Form Drug Product Portfolio Table 134. Astellas Recent Development Table 135. Research Programs/Design for This Report Table 136. Authors List of This Report Table 137. Secondary Sources Table 138. Primary Sources List of Figures Figure 1. Solid Dosage Form Drug Product Image Figure 2. Global Solid Dosage Form Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Solid Dosage Form Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Solid Dosage Form Drug Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Tablet Image Figure 8. Capsules Image Figure 9. Other Image Figure 10. Global Solid Dosage Form Drug Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Solid Dosage Form Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Solid Dosage Form Drug Sales Value Share by Type (2021-2032) Figure 13. Hospital Image Figure 14. Retail Pharmacy Image Figure 15. Other Image Figure 16. Global Solid Dosage Form Drug Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Solid Dosage Form Drug Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Solid Dosage Form Drug Sales Value Share by Application (2021-2032) Figure 19. Global Solid Dosage Form Drug Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Solid Dosage Form Drug Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Solid Dosage Form Drug Sales Value (2021-2032) & (US$ Million) Figure 22. North America Solid Dosage Form Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Solid Dosage Form Drug Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Solid Dosage Form Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Solid Dosage Form Drug Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Solid Dosage Form Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Solid Dosage Form Drug Sales Value (2021-2032) & (US$ Million) Figure 28. South America Solid Dosage Form Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Solid Dosage Form Drug Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Solid Dosage Form Drug Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Solid Dosage Form Drug Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Tablet
  • Capsules
  • Other
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Takeda
  • Teva
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Roche
  • Eli Lilly & Co.
  • Pfizer
  • GlaxoSmithKline
  • Biogen
  • Bayer
  • Bristol Myers Squibb
  • Amgen
  • AbbVie
  • AstraZeneca
  • Merck & Co.
  • Gilead Sciences
  • Boehringer Ingelheim
  • Astellas

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Solid Dosage Form Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Solid Dosage Form Drug Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Solid Dosage Form Drug Market Dynamics
  1. 2.1 Solid Dosage Form Drug Industry Trends
  2. 2.2 Solid Dosage Form Drug Industry Drivers
  3. 2.3 Solid Dosage Form Drug Industry Opportunities and Challenges
  4. 2.4 Solid Dosage Form Drug Industry Restraints
3 Solid Dosage Form Drug Market by Company
  1. 3.1 Global Solid Dosage Form Drug Company Revenue Ranking in 2025
  2. 3.2 Global Solid Dosage Form Drug Revenue by Company (2021-2026)
  3. 3.3 Global Solid Dosage Form Drug Company Ranking (2024-2026)
  4. 3.4 Global Solid Dosage Form Drug Company Manufacturing Base and Headquarters
  5. 3.5 Global Solid Dosage Form Drug Company Product Type and Application
  6. 3.6 Global Solid Dosage Form Drug Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Solid Dosage Form Drug Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Solid Dosage Form Drug Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Solid Dosage Form Drug Market by Type
  1. 4.1 Solid Dosage Form Drug Type Introduction
  2. 4.1.1 Tablet
  3. 4.1.2 Capsules
  4. 4.1.3 Other
  5. 4.2 Global Solid Dosage Form Drug Sales Value by Type
  6. 4.2.1 Global Solid Dosage Form Drug Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Solid Dosage Form Drug Sales Value by Type (2021-2032)
  8. 4.2.3 Global Solid Dosage Form Drug Sales Value Share by Type (2021-2032)
5 Solid Dosage Form Drug Market by Application
  1. 5.1 Solid Dosage Form Drug Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Retail Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Solid Dosage Form Drug Sales Value by Application
  6. 5.2.1 Global Solid Dosage Form Drug Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Solid Dosage Form Drug Sales Value by Application (2021-2032)
  8. 5.2.3 Global Solid Dosage Form Drug Sales Value Share by Application (2021-2032)
6 Solid Dosage Form Drug Regional Value Analysis
  1. 6.1 Global Solid Dosage Form Drug Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Solid Dosage Form Drug Sales Value by Region (2021-2032)
  3. 6.2.1 Global Solid Dosage Form Drug Sales Value by Region: 2021-2026
  4. 6.2.2 Global Solid Dosage Form Drug Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Solid Dosage Form Drug Sales Value (2021-2032)
  7. 6.3.2 North America Solid Dosage Form Drug Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Solid Dosage Form Drug Sales Value (2021-2032)
  10. 6.4.2 Europe Solid Dosage Form Drug Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Solid Dosage Form Drug Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Solid Dosage Form Drug Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Solid Dosage Form Drug Sales Value (2021-2032)
  16. 6.6.2 South America Solid Dosage Form Drug Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Solid Dosage Form Drug Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Solid Dosage Form Drug Sales Value Share by Country, 2025 VS 2032
7 Solid Dosage Form Drug Country-level Value Analysis
  1. 7.1 Global Solid Dosage Form Drug Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Solid Dosage Form Drug Sales Value by Country (2021-2032)
  3. 7.2.1 Global Solid Dosage Form Drug Sales Value by Country (2021-2026)
  4. 7.2.2 Global Solid Dosage Form Drug Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Solid Dosage Form Drug Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Solid Dosage Form Drug Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Solid Dosage Form Drug Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Solid Dosage Form Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Teva
  8. 8.2.1 Teva Company Information
  9. 8.2.2 Teva Business Overview
  10. 8.2.3 Teva Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Teva Solid Dosage Form Drug Product Portfolio
  12. 8.2.5 Teva Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Solid Dosage Form Drug Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Johnson & Johnson
  20. 8.4.1 Johnson & Johnson Company Information
  21. 8.4.2 Johnson & Johnson Business Overview
  22. 8.4.3 Johnson & Johnson Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Johnson & Johnson Solid Dosage Form Drug Product Portfolio
  24. 8.4.5 Johnson & Johnson Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Solid Dosage Form Drug Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Roche
  32. 8.6.1 Roche Company Information
  33. 8.6.2 Roche Business Overview
  34. 8.6.3 Roche Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Roche Solid Dosage Form Drug Product Portfolio
  36. 8.6.5 Roche Recent Developments
  37. 8.7 Eli Lilly & Co.
  38. 8.7.1 Eli Lilly & Co. Company Information
  39. 8.7.2 Eli Lilly & Co. Business Overview
  40. 8.7.3 Eli Lilly & Co. Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Eli Lilly & Co. Solid Dosage Form Drug Product Portfolio
  42. 8.7.5 Eli Lilly & Co. Recent Developments
  43. 8.8 Pfizer
  44. 8.8.1 Pfizer Company Information
  45. 8.8.2 Pfizer Business Overview
  46. 8.8.3 Pfizer Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Pfizer Solid Dosage Form Drug Product Portfolio
  48. 8.8.5 Pfizer Recent Developments
  49. 8.9 GlaxoSmithKline
  50. 8.9.1 GlaxoSmithKline Company Information
  51. 8.9.2 GlaxoSmithKline Business Overview
  52. 8.9.3 GlaxoSmithKline Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GlaxoSmithKline Solid Dosage Form Drug Product Portfolio
  54. 8.9.5 GlaxoSmithKline Recent Developments
  55. 8.10 Biogen
  56. 8.10.1 Biogen Company Information
  57. 8.10.2 Biogen Business Overview
  58. 8.10.3 Biogen Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Biogen Solid Dosage Form Drug Product Portfolio
  60. 8.10.5 Biogen Recent Developments
  61. 8.11 Bayer
  62. 8.11.1 Bayer Company Information
  63. 8.11.2 Bayer Business Overview
  64. 8.11.3 Bayer Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Bayer Solid Dosage Form Drug Product Portfolio
  66. 8.11.5 Bayer Recent Developments
  67. 8.12 Bristol Myers Squibb
  68. 8.12.1 Bristol Myers Squibb Company Information
  69. 8.12.2 Bristol Myers Squibb Business Overview
  70. 8.12.3 Bristol Myers Squibb Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Bristol Myers Squibb Solid Dosage Form Drug Product Portfolio
  72. 8.12.5 Bristol Myers Squibb Recent Developments
  73. 8.13 Amgen
  74. 8.13.1 Amgen Company Information
  75. 8.13.2 Amgen Business Overview
  76. 8.13.3 Amgen Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Amgen Solid Dosage Form Drug Product Portfolio
  78. 8.13.5 Amgen Recent Developments
  79. 8.14 AbbVie
  80. 8.14.1 AbbVie Company Information
  81. 8.14.2 AbbVie Business Overview
  82. 8.14.3 AbbVie Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  83. 8.14.4 AbbVie Solid Dosage Form Drug Product Portfolio
  84. 8.14.5 AbbVie Recent Developments
  85. 8.15 AstraZeneca
  86. 8.15.1 AstraZeneca Company Information
  87. 8.15.2 AstraZeneca Business Overview
  88. 8.15.3 AstraZeneca Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  89. 8.15.4 AstraZeneca Solid Dosage Form Drug Product Portfolio
  90. 8.15.5 AstraZeneca Recent Developments
  91. 8.16 Merck & Co.
  92. 8.16.1 Merck & Co. Company Information
  93. 8.16.2 Merck & Co. Business Overview
  94. 8.16.3 Merck & Co. Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Merck & Co. Solid Dosage Form Drug Product Portfolio
  96. 8.16.5 Merck & Co. Recent Developments
  97. 8.17 Gilead Sciences
  98. 8.17.1 Gilead Sciences Company Information
  99. 8.17.2 Gilead Sciences Business Overview
  100. 8.17.3 Gilead Sciences Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Gilead Sciences Solid Dosage Form Drug Product Portfolio
  102. 8.17.5 Gilead Sciences Recent Developments
  103. 8.18 Boehringer Ingelheim
  104. 8.18.1 Boehringer Ingelheim Company Information
  105. 8.18.2 Boehringer Ingelheim Business Overview
  106. 8.18.3 Boehringer Ingelheim Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Boehringer Ingelheim Solid Dosage Form Drug Product Portfolio
  108. 8.18.5 Boehringer Ingelheim Recent Developments
  109. 8.19 Astellas
  110. 8.19.1 Astellas Company Information
  111. 8.19.2 Astellas Business Overview
  112. 8.19.3 Astellas Solid Dosage Form Drug Revenue and Gross Margin (2021-2026)
  113. 8.19.4 Astellas Solid Dosage Form Drug Product Portfolio
  114. 8.19.5 Astellas Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst